Cimaher Use In Pregnancy & Lactation

Use in pregnancy: Effects of nimotuzumab on pregnancy have not been studied. However, animal studies have shown that at the embryonic stage, lack of EGFR can cause lack of maturation of the epithelium and postnatal death. EGFR has been implicated in the control of prenatal development and hence may be essential for normal organogenesis, proliferation and differentiation in the developing embryo. Human IgG1 is known to cross the placental barrier; therefore the antibody has the potential to be transmitted from the mother to the developing fetus. The use of Nimotuzumab during pregnancy is not recommended. The antibody should only be given to a pregnant woman, or any woman not employing adequate contraception if the potential benefit outweighs the potential risks to the fetus. If the patient becomes pregnant while receiving this drug, she should be informed of the potential hazard to the fetus and/or the potential risk of loss of the pregnancy.
Use in lactation: Nimotuzumab is secreted in human milk, therefore it is not recommended to use in lactating women. No recommendation is made on the potential benefit versus risk of administering Nimotuzumab to nursing mothers.